← Back to search
GLAXOSMITHKLINE BIOLOGICALS
Doing business as SMITHKLINE BEECHAM BIOLOGICALS
RIXENSART, 1330
UnclaimedClaim this profile (free)
Subcontracting experience
2 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Subcontractor | Department of Health and Human Services | STREP A IS A GRAM-POSITIVE BACTERIUM WITH A RICH REPERTOIRE OF VIRULENCE FACTORS THAT ALLOWS FOR A WIDE SPECTRUM OF CLINICAL MANIFESTATIONS. STREP A IS THE COMMON CAUSE OF BACTERIAL SORE THROATS (PHARYNGITIS) AND SKIN INFECTIONS (IMPETIGO) BUT THE RANGE OF DISEASES CAUSED BY THIS PATHOGEN EXTENDS FROM THESE COMMON SUPERFICIAL INFECTIONS TO MORE COMPLICATED CLINICAL OUTCOMES SUCH AS INVASIVE DISEASES (E.G., CELLULITIS AND SEPSIS), TOXIN-MEDIATED DISEASES (E.G., SCARLET FEVER, TOXIC SHOCK SYNDROME AND NECROTIZING FASCIITIS) AND AUTOIMMUNE SEQUELAE (E.G., ACUTE RHEUMATIC FEVER, ARF; RHEUMATIC HEART DISEASE, RHD; AND POST-STREPTOCOCCAL GLOMERULONEPHRITIS, PSGN). ACCORDING TO THE WHO, STREP A ACCOUNTS FOR MORE THAN 0.5 MILLION DEATHS EACH YEAR, A SIMILAR DEATH TOLL TO MALARIA. MOST DEATHS ARE CAUSED BY RHD, AN AUTOIMMUNE SYNDROME CAUSED BY REPEATED UNDERTREATED SUPERFICIAL STREP A INFECTIONS (E.G., PHARYNGITIS AND IMPETIGO), AND MOST OF THIS BURDEN LIES IN IMPOVERISHED COMMUNITIES WHERE POOR SANITIZATION, OVERCROWDING, MALNUTRITION AND LACK OF ACCESS TO HEALTHCARE PREVAIL. STREP A IS STRICTLY A HUMAN PATHOGEN AND COMMUNITIES IN SETTINGS OF EXTREME POVERTY ARE EASY TARGETS FOR THIS HIGHLY INFECTIOUS MICROORGANISM. PHARYNGITIS (>616 MILLION CASES PER YEAR) AND IMPETIGO (>162 MILLION CASES PER YEAR) ARE RESPONSIBLE FOR THE GREATEST ABSOLUTE NUMBER OF STREP A CLINICAL MANIFESTATIONS. THEY ARE NOT ONLY RESPONSIBLE FOR THE DEVELOPMENT OF AUTOIMMUNE SEQUELAE (ARF AND RHD) BUT ALSO FOR ANTIBIOTIC TREATMENTS THAT ARE FREQUENTLY INCONSISTENT WITH GUIDELINES: I) BROAD-SPECTRUM ANTIBIOTICS ARE OFTEN USED UNNECESSARILY, II) OVER-THE-COUNTER OVERUSE IN DEVELOPING COUNTRIES, III) INAPPROPRIATE PRESCRIPTIONS OF ANTIBIOTICS (>1/3) FOR SORE THROATS DUE TO VIRAL INFECTIONS. SORE THROATS AND IMPETIGO ARE TYPICALLY TREATED WITH 5-10 GRAMS OF AMPICILLIN PER REGIMEN THAT, TOGETHER, COULD ACCOUNT FOR >4 THOUSAND TONS OF ANTIBIOTICS USED IN THE APPROPRIATE AND INAPPROPRIATE TREATMENT OF STREP A INFECTIONS PER YEAR, WHICH CONTRIBUTE TO THE LONG-TERM DYSBIOSIS OF COMMENSAL FLORA AND EMERGENCE OF ANTIBIOTIC RESISTANCE. THEREFORE, THE PREVENTION OF STREP A SUPERFICIAL INFECTIONS BY A VACCINE WOULD NOT ONLY PREVENT THE BURDEN ASSOCIATED WITH PHARYNGITIS AND IMPETIGO BUT ALSO ASSOCIATED ANTIBIOTIC PRESCRIPTIONS AND THE AUTOIMMUNE CONSEQUENCES OF THESE INFECTIONS. GSK STREP A VACCINE AIMS TO REDUCE AND PREVENT THE INCIDENCE AND SEVERITY OF STREP A SUPERFICIAL INFECTIONS (E.G., PHARYNGITIS AND IMPETIGO) AND CONSEQUENTLY REDUCE THE GLOBAL BURDEN OF ASSOCIATED AUTOIMMUNE SEQUELAE (ARF AND RHD) AND ASSOCIATED ANTIBIOTIC PRESCRIPTIONS, WHICH ARE THE BASIS FOR THE INCREASED ANTIBIOTIC RESISTANCE OF THIS PATHOGEN AND BYSTANDER SELECTIVE PRESSURE ON THE HUMAN MICROBIOME. IN THE CARB-X OPTION STAGE, GSK WILL PERFORM A PHASE 1 DOSE-ESCALATION STUDY IN HEALTHY ADULTS WITH A SAFETY AND IMMUNOGENICITY OUTCOME. OUR LONG-TERM VISION AND KEY STRATEGIC GOALS ARE TIGHTLY ALIGNED WITH THE WHO, AS DESCRIBED IN ITS PREFERRED PRODUCT CHARACTERISTICS (PPC) AND TECHNOLOGY ROADMAP FOR A STREP A VACCINE: “A SAFE, GLOBALLY EFFECTIVE AND AFFORDABLE STREP A VACCINE IS NEEDED TO PREVENT AND POTENTIALLY ELIMINATE ACUTE STREP A INFECTIONS (PHARYNGITIS, SKIN INFECTIONS, CELLULITIS, INVASIVE DISEASE) AND ASSOCIATED ANTIBIOTIC USE, IMMUNE-MEDIATED SEQUELAE (KIDNEY DISEASE, ARF AND RHD) AND ASSOCIATED MORTALITY”. ALTHOUGH LOW- AND MIDDLE-INCOME COUNTRIES WOULD MAINLY BENEFIT FROM STREP A VACCINES, CONSIDERING THAT AN ESTIMATED 82% OF THE RHD DEATHS OCCURS IN REGIONS WITH AN ENDEMIC DISEASE PATTERN, AN EFFECTIVE VACCINE WOULD HAVE GLOBAL IMPLICATIONS. KC3400 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541714 Parent award performance state: MA Parent award description: CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA View parent award on USAspending | — | $2,309,512 | Feb 9, 2023 | — – — |
| Subcontractor | Department of Health and Human Services | A TRIVALENT SALMONELLA VACCINE AGAINST INVASIVE NONTYPHOIDAL SALMONELLOSIS (INTS) AND TYPHOID FEVER, INTS-TYPHOID CONJUGATE VACCINE (TCV), IS NEEDED FOR SUB-SAHARAN AFRICA (SSA) TO IMPACT DISEASE BURDEN IN VERY YOUNG CHILDREN AND CONTRIBUTE TO ANTIBIOTIC STEWARDSHIP DUE TO THE HIGH ANTIMICROBIAL RESISTANCE (AMR) ASSOCIATED WITH SALMONELLA. THE PROJECT CONDUCTED BY GSK, THROUGH GSK VACCINES INSTITUTE FOR GLOBAL HEALTH, IS SUPPORTED BY BIOLOGICAL E LTD, HYDERABAD, INDIA.
INTS IS AN UNDER-RECOGNIZED HIGHLY INVASIVE DISEASE CAUSED MAINLY BY S. ENTERITIDIS AND S. TYPHIMURIUM STRAINS THAT CARRY MULTIPLE AMR MARKERS AND SHOW REDUCED SENSITIVITY TO FLUOROQUINOLONES. IN 2017, INTS BURDEN IN SSA WAS >400,000 CASES WITH ~50,000 DEATHS. S. TYPHI HAS WIDESPREAD FLUOROQUINOLONE RESISTANCE AND IN AFRICA AMR IS INCREASING. IN SSA, THERE ARE 1.5 MILLION CASES OF TYPHOID FEVER AND 20,000 DEATHS/YEAR. INTS-TCV WOULD ADD TO THE GAVI ROLLOUT OF TYPHOID VACCINES IN SSA, PREVENTING 70,000 DEATHS/YEAR FROM BOTH DISEASES AT MINIMAL ADDITIONAL EXPENSE, THUS ADDRESSING A MAJOR IMPEDIMENT TO AN INTS VACCINE, THE COMMERCIAL SUSTAINABILITY.
THIS PROJECT FORMULATES INTS-TCV FROM EXISTING VACCINE TECHNOLOGIES AND WILL TEST IT IN A 2-SITE PHASE 1 TRIAL IN EUROPEAN AND AFRICAN ADULTS. THE INTS COMPONENTS USE THE GMMA-TECHNOLOGY, IDEAL BECAUSE PRODUCTION IS SIMPLE, ROBUST AND YIELDS ARE HIGH. THE TYPHOID COMPONENT IS A LOW-COST TCV FROM BIOLOGICAL E. THIS WEDDING OF TWO ASSETS COULD RAPIDLY RESULT IN AN EFFECTIVE, AFFORDABLE AND SUSTAINABLE VACCINE TO BE DELIVERED TO POPULATIONS AT RISK, PROTECT AGAINST BOTH INTS AND TYPHOID FEVER, AND REDUCE ANTIBIOTIC USE IN SSA. THIS LOW RISK AND HIGH IMPACT PRODUCT DEVELOPMENT, WITH UNIQUE PROGRAMMATIC ADVANTAGES OVER SEPARATE ADMINISTRATION OF TCV AND INTS-GMMA VACCINES, MAY BE THE ONLY VIABLE OPTION FOR A SUSTAINABLE INTS VACCINE IN SSA. IT TRULY MEETS THE CARB-X GOAL OF GETTING €œTHE VACCINE TO A POINT WHERE IT CAN ATTRACT INVESTMENT FOR CLINICAL DEVELOPMENT€Ͽ½. 4500004535 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541714 Parent award performance state: MA Parent award description: CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA View parent award on USAspending | — | $158,021 | Feb 9, 2023 | — – — |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Government-sourced data comes from SAM.gov, SBA and USAspending.gov and is attributed to its source. Items marked company-reported were provided by the company and are verified by FedSub only where labeled. FedSub is a private company and is not affiliated with SBA, GSA/SAM.gov, or any government agency.